Company: HCTI
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112544
Chunk: 47

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 47
---
; |

| ● | Diluting                              
 the voting power of the common stock; |

| ● | Impairing                                      
 the liquidation rights of the common stock; or |

| ● | Delaying                                                                             
 or preventing a change in control of the Company without consent of the stockholders |

Transfer Agent and Registrar

The transfer agent and registrar for our common
stock will be VStock Transfer, LLC.

<div align='center'>16

DESCRIPTION OF WARRANTS</div>

General

As of January 4, 2024, warrants to purchase approximately
609,756 shares of our common stock with a weighted average exercise price per share of $10.66 were outstanding.

We may offer by means of this prospectus warrants
for the purchase of our common stock or preferred stock. We may issue warrants separately or together with any other securities offered
by means of this prospectus, and the warrants may be attached to or separate from such securities. Each series of warrants will be issued
under a separate warrant agreement to be entered into between us and a warrant agent specified therein. The warrant agent will act solely
as our agent in connection with the warrants of such series and will not assume any obligation or relationship of agency or trust for
or with any holders or beneficial owners of warrants.

When we refer to a series of securities in this
section, we mean all securities issued as part of the same series under any applicable indenture, agreement, or other instrument. When
we refer to the prospectus supplement, we mean the applicable prospectus supplement describing the specific terms of the security you
purchase. The terms used in the prospectus supplement will have the meanings described in this prospectus, unless otherwise specified.

The following description of warrants does not
purport to be complete and is qualified in its entirety by reference to the description of a particular series of warrants contained in
an applicable prospectus supplement. For information relating to our capital stock, see “Description of Common Stock,”
and “Description of Preferred Stock.”

Agreements

Unless otherwise provided in the applicable prospectus
supplement, the following provisions will apply to any warrants we issue pursuant to this prospectus. Each series of warrants may be evidenced
by certificates and may be issued under a separate indenture, agreement, or other instrument to be entered into between us and a bank
that we select as agent with respect to such series. The agent, if any, will have its principal office in the United States and have a
combined capital and surplus of at least $